Your browser doesn't support javascript.
Cellular interferon-gamma and interleukin-2 responses to SARS-CoV-2 structural proteins are broader and higher in those vaccinated after SARS-CoV-2 infection compared to vaccinees without prior SARS-CoV-2 infection.
Sedegah, Martha; Porter, Chad; Goguet, Emilie; Ganeshan, Harini; Belmonte, Maria; Huang, Jun; Belmonte, Arnel; Inoue, Sandra; Acheampong, Neda; Malloy, Allison M W; Hollis-Perry, Monique; Jackson-Thompson, Belinda; Ramsey, Kathy F; Alcorta, Yolanda; Maiolatesi, Santina E; Wang, Gregory; Reyes, Anatolio E; Illinik, Luca; Sanchez-Edwards, Margaret; Burgess, Timothy H; Broder, Christopher C; Laing, Eric D; Pollett, Simon D; Villasante, Eileen; Mitre, Edward; Hollingdale, Michael R.
  • Sedegah M; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Porter C; Translational Clinical Research Department, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Goguet E; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
  • Ganeshan H; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
  • Belmonte M; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Huang J; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
  • Belmonte A; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Inoue S; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
  • Acheampong N; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Malloy AMW; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
  • Hollis-Perry M; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Jackson-Thompson B; General Dynamics Information Technology, Falls Church, VA, United States of America.
  • Ramsey KF; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Alcorta Y; General Dynamics Information Technology, Falls Church, VA, United States of America.
  • Maiolatesi SE; Agile Vaccines and Therapeutics, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Wang G; General Dynamics Information Technology, Falls Church, VA, United States of America.
  • Reyes AE; Department of Pediatrics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
  • Illinik L; Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Sanchez-Edwards M; Department of Microbiology and Immunology, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
  • Burgess TH; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
  • Broder CC; General Dynamics Information Technology, Falls Church, VA, United States of America.
  • Laing ED; Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Pollett SD; Infectious Diseases Clinical Research Program, Department of Preventive Medicine and Biostatistics, Uniformed Services University of the Health Sciences, Bethesda, MD, United States of America.
  • Villasante E; General Dynamics Information Technology, Falls Church, VA, United States of America.
  • Mitre E; Clinical Trials Center, Naval Medical Research Center, Silver Spring, MD, United States of America.
  • Hollingdale MR; Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc., Bethesda, MD, United States of America.
PLoS One ; 17(10): e0276241, 2022.
Article in English | MEDLINE | ID: covidwho-2079762
ABSTRACT
Class I- and Class II-restricted epitopes have been identified across the SARS-CoV-2 structural proteome. Vaccine-induced and post-infection SARS-CoV-2 T-cell responses are associated with COVID-19 recovery and protection, but the precise role of T-cell responses remains unclear, and how post-infection vaccination ('hybrid immunity') further augments this immunity To accomplish these goals, we studied healthy adult healthcare workers who were (a) uninfected and unvaccinated (n = 12), (b) uninfected and vaccinated with Pfizer-BioNTech BNT162b2 vaccine (2 doses n = 177, one dose n = 1) or Moderna mRNA-1273 vaccine (one dose, n = 1), and (c) previously infected with SARS-CoV-2 and vaccinated (BNT162b2, two doses, n = 6, one dose n = 1; mRNA-1273 two doses, n = 1). Infection status was determined by repeated PCR testing of participants. We used FluoroSpot Interferon-gamma (IFN-γ) and Interleukin-2 (IL-2) assays, using subpools of 15-mer peptides covering the S (10 subpools), N (4 subpools) and M (2 subpools) proteins. Responses were expressed as frequencies (percent positive responders) and magnitudes (spot forming cells/106 cytokine-producing peripheral blood mononuclear cells [PBMCs]). Almost all vaccinated participants with no prior infection exhibited IFN-γ, IL-2 and IFN-γ+IL2 responses to S glycoprotein subpools (89%, 93% and 27%, respectively) mainly directed to the S2 subunit and were more robust than responses to the N or M subpools. However, in previously infected and vaccinated participants IFN-γ, IL-2 and IFN-γ+IL2 responses to S subpools (100%, 100%, 88%) were substantially higher than vaccinated participants with no prior infection and were broader and directed against nine of the 10 S glycoprotein subpools spanning the S1 and S2 subunits, and all the N and M subpools. 50% of uninfected and unvaccinated individuals had IFN-γ but not IL2 or IFN-γ+IL2 responses against one S and one M subpools that were not increased after vaccination of uninfected or SARS-CoV-2-infected participants. Summed IFN-γ, IL-2, and IFN-γ+IL2 responses to S correlated with IgG responses to the S glycoprotein. These studies demonstrated that vaccinations with BNT162b2 or mRNA-1273 results in T cell-specific responses primarily against epitopes in the S2 subunit of the S glycoprotein, and that individuals that are vaccinated after SARS-CoV-2 infection develop broader and greater T cell responses to S1 and S2 subunits as well as the N and M proteins.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon-gamma / Interleukin-2 / COVID-19 Topics: Vaccines Limits: Adult / Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0276241

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Interferon-gamma / Interleukin-2 / COVID-19 Topics: Vaccines Limits: Adult / Humans Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0276241